Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Galileo: VX-670 in Adult Subjects With Myotonic Dystrophy Type 1
NCT06185764Phase 2Active, not recruiting
- Sponsor
- Vertex Pharmaceuticals
- Start
- Feb 2024
- Primary completion
- Feb 2027
- Modality
- Antisense DNA, Small Interfering RNA (siRNA), Antisense Oligonucleotides (ASOs)
- Countries
- 10
01
Overview
A Phase 2 trial of VX-670 in myotonic dystrophy type 1 (DM1), sponsored by Vertex Pharmaceuticals. Started Feb 2024; status: active, not recruiting.
02
Drugs
VX-670
03
Conditions
myotonic dystrophy type 1 (DM1)
Beyond the preview
Go deeper on NCT06185764.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06185764.